+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

DNA Damage Response Targeting Therapeutics Market by Target Disease Indication, Therapeutic Area, Target Molecule, Type of Molecule, Route of Administration, and by Key Geographical Regions: Industry Trends and Global Forecasts, 2021-2030

  • ID: 5441009
  • Report
  • June 2021
  • Region: Global
  • 265 Pages
  • Roots Analysis

FEATURED COMPANIES

  • 5AM Ventures
  • Bayer
  • Cyteir Therapeutics
  • Kazan Federal University
  • OrbiMed
  • Shinsei Capital Partners

Overview

According to the WHO, cancer is presently the second leading cause of death, worldwide. As per GLOBOCAN, the number of patients diagnosed with various types of cancer in the US, crossed the 19 million mark in 2020. By 2030, it is estimated that the aforementioned number is likely to grow to over 22 million. Over time, it has been established that the conventional approaches, such as chemotherapy, surgery and radiation therapy, to treating oncological indication(s) are inadequate, especially when it comes to late-stage cancers. In fact, several of the traditional interventions are designed to eliminate cancerous tissue by damaging the genetic material (DNA) contained in the malignantly transformed cells, in order to trigger programmed cell death. However, if the therapeutic-induced DNA damage is repaired, the cells survive. This is also the basis for why specific patient populations become resistant to certain forms of therapy. Over the years, scientific enquiry into the genetic causes of the malignant transformation have recognized defects and tumor microenvironment induced upregulation of specific cellular pathways, which are deemed to be responsible for the identification / repair of DNA damage and the resulting resistance to the traditional forms of treatment. These are now considered to be reliable disease biomarkers and thereby, viable biological targets for targeted drug development initiatives. 

The DNA damage response (DDR) comprises of orchestrated network of pathways that signal not only for repair of DNA lesions but also for activation of checkpoints, which are responsible for cell arrest at key points in the cell cycle. Importantly, high specificity and sensitivity to conventional therapies, coupled to minimal off target toxicity, have led to the use of DDR as a potential target for treatment of wider range of clinical conditions (both oncological and non-oncological). In this regard, several researchers across the globe have developed / developing DDR inhibitors to overcome DDR-mediated resistance to DNA-damaging anticancer therapy and exploit DDR dysfunction in oncological indication by targeting alternative pathways. 

Currently, there are four approved poly-ADP ribose polymerase (PARP) inhibitor drugs that are based on the inhibition of the DNA damage repair process in advanced stage oncological indications. Further, drug developers across the world, claim to be evaluating several other molecular targets, such as ATM, ATR, CHK1, and WEE1, within the DNA damage response pathway. Although majority of the drug candidates for molecular targets (other than PARP) are in the preclinical / initial clinical stages, drug developers are optimistic regarding the therapeutic potential of this emerging class of drugs. Gradually, a substantial body of evidence, validating the efficacy of drugging the aforementioned biological targets, is being generated through extensive research in this field; this is reflected in the rapidly growing number of research publications and patents focused on this subject. Driven by encouraging clinical trial results, this niche, but upcoming market, is poised to witness healthy growth over the next decade, with pioneers in the field likely to benefit from the first-to-market advantage.

Scope of the Report

The “DNA Damage Response Targeting Therapeutics (beyond PARP inhibitors) Market by Target Disease Indication (Acute Myeloid Leukemias, COVID-19, Diabetic Macular Edemas, Mesotheliomas, Myelodysplastic Syndromes, Non-Squamous Non-Small Cell Lung Cancers, Prostate Cancers, Uterine Serous Carcinomas), Therapeutic Area (Hematological Malignancies, Solid Tumors, and Other Disorders), Target Molecule (APE1/Ref-1, Casein Kinase 2, CHK-1, C-Tak, DHODH, MAPKAPK2, p53, and WEE 1), Type of Molecule (Biologics and Small Molecule), Route of Administration (Oral Drugs and Intravenous Drugs), and by Key Geographical Regions (US, Canada, Denmark, France, Germany, Italy, Spain, UK, Australia, Singapore, and South Korea): Industry Trends and Global Forecasts, 2021-2030” report features an extensive study of the current landscape, offering an informed opinion on the likely adoption of DNA damage response targeting therapeutics in the healthcare industry, over the next decade. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. 

Amongst other elements, the report includes:

  • A detailed review of the current market landscape of DNA damage response targeting therapeutics, including information on phase of development (clinical and preclinical), target disease indication(s), therapeutic area (hematological malignancies, immune-oncological disorders, neurological disorders, solid tumors, unspecified oncological disorders, and other disorders), target molecule, type of molecule (biological and small molecules), type of therapy (monotherapies, and combination therapies), dosage form (solid, and liquid), route of administration (intravenous, subcutaneous, and oral), and special drug designation awarded (if any). In addition, it highlights the companies engaged in the development of DNA damage response targeting therapeutics, along with information on their year of establishment, company size (in terms of employee count) and location of respective headquarters.
  • An in-depth analysis of the contemporary market trends, presented using four schematic representations, including [A] a bubble analysis comparing the leading players engaged in this domain, based on several relevant parameters (such as product portfolio strength, phase of development and company size), [B] an insightful tree map representation of DNA damage response targeting therapeutics developers, based on their target therapeutic area and company size, [C] a world map representation highlighting the regional distribution of developers engaged in this domain, and [D] a grid representation illustrating the distribution of DNA damage response targeting therapeutics based on their phase of development, target therapeutic area, type of molecule, type of therapy, and route of administration.
  • Elaborate profiles of prominent players engaged in the development of DNA damage response targeting therapeutics. Each profile features a brief overview of the company, details related to its respective drug candidates, recent developments and an informed future outlook.
  • A detailed analysis of more than 250 completed, ongoing and planned clinical studies of various DNA damage response targeting therapeutics, based on several relevant parameters, such as trial registration year, number of patients enrolled, gender of patients enrolled, trial phase, recruitment status and study design, highlighting leading sponsors / collaborators and leading players (in terms of number of trials conducted), type of organization, popular therapeutic areas and regional distribution of trials. In addition, it features an insightful case study (for trials related to clinical DNA damage response targeting therapeutics, within the scope of the report).
  • An analysis of more than 150 peer-reviewed scientific articles related to DNA damage response targeting therapeutics, published during the period April 2020 to March 2021, highlighting the research focus within this niche industry segment. Additionally, it features an informed opinion on the key trends observed across the aforementioned publications, including information on target disease indications, and analysis based on several relevant parameters, such as year of publication, type of publication, key research hubs, most popular authors, provision of grant awarded, target molecule, and most popular journals (in terms of number of articles published in the given time period and journal impact factor). Further, it includes a multivariate publication attractiveness analysis based on various parameters, such as type of publication, grant support, journal impact factor, and number of target molecules under study.
  • An insightful multivariate scenario management analysis impacting adoption rates and price points taking into consideration more than 20 parameters.

One of the key objectives of the report was to estimate the existing market size and future opportunity for DNA damage response targeting therapeutics developers, over the next decade. Further, we have provided an informed estimate of the evolution of the market, during the period 2021-2030, based on several relevant parameters, such as adoption trends, and expected price variations for these products. Additionally, the report features the likely distribution of the current and forecasted opportunity within DNA damage response targeting therapeutics market across [A] target disease indications (acute myeloid leukemias, COVID-19, diabetic macular edemas, mesotheliomas, myelodysplastic syndromes, non-squamous non-small cell lung cancers, prostate cancers, and uterine serous carcinomas), [B] therapeutic areas (hematological malignancies, solid tumors, and other disorders), [C] target molecule (APE/REF-1, casein kinase 2, CHK-1, C-Tak, DHODH, MAPKAPK2, p53, and WEE 1), [D] type of molecule (biologics and small molecule), [E] route of administration (oral drugs and intravenous drugs), and [F] key geographical regions (US, Canada, Denmark, France, Germany, Italy, Spain, UK, Australia, Singapore, and South Korea). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading players engaged in the development of DNA damage response targeting therapeutics?
  • Which popular molecules are being targeted by DNA damage response targeting therapeutics?
  • Which companies are actively involved in conducting clinical trials for their therapeutics? 
  • What is the evolving trend related to the focus of publications related to DNA damage response targeting therapeutics?
  • What are key factors impacting the pricing and adoption of DNA damage response targeting therapeutics?
  • What opportunities are available for DNA damage response targeting therapeutics in emerging markets?
  • How is the current and future opportunity likely to be distributed across key market segments?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 5AM Ventures
  • Bayer
  • Cyteir Therapeutics
  • Kazan Federal University
  • OrbiMed
  • Shinsei Capital Partners

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of DNA Damage
3.3. DNA Damaging Agents
3.4. DNA Damage Response Systems
3.4.1. Key Components of DNA Repair Pathways
3.5. Types of DNA Repair Pathways
3.5.1. Direct Pathways
3.5.2. Excision Repair Pathway
3.5.2.1. Base Excision Repair Pathway
3.5.2.2. Nucleotide Excision Repair Pathway
3.5.2.3. Mismatch Repair Pathway
3.5.3. Indirect Pathways
3.5.3.1. Homologous Recombination (HR) Repair Pathway
3.5.3.2. Non-homologous End Joining (NHEJ) Repair Pathway
3.6. Concluding Remarks

4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. DNA Damage Response Targeting Therapeutics: Clinical Pipeline
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Target Disease Indication(s)
4.2.3. Analysis by Therapeutic Area
4.2.4. Analysis by Target Molecule
4.2.5. Analysis by Type of Molecule
4.2.6. Analysis by Type of Therapy
4.2.7. Analysis by Dosage Form
4.2.8. Analysis by Route of Administration
4.2.9. Analysis by Special Drug Designation Awarded
4.3. DNA Damage Response Targeting Therapeutics: Preclinical Pipeline
4.3.1. Analysis by Phase of Development
4.3.2. Analysis by Target Disease Indication(s)
4.3.3. Analysis by Therapeutic Area
4.3.4. Analysis by Type of Molecule
4.3.5. Analysis by Type of Therapy
4.4 DNA Damage Response Targeting Therapeutics: List of Developers
4.4.1. Analysis by Year of Establishment
4.4.2. Analysis by Company Size
4.4.3. Analysis by Location of Headquarters
4.4.4. Leading Developers: Analysis by Number of Proprietary Product Candidates

5. KEY INSIGHTS
5.1. Chapter Overview
5.2. Analysis by Portfolio Strength, Phase of Development and Company Size (4D Bubble Chart)
5.3. Analysis by Therapeutic Area and Company Size (Treemap Representation)
5.4. Analysis by Location of Headquarters (World Map Representation)
5.5. Analysis by Phase of Development, Therapeutic Area, Type of Molecule, Type of Therapy and Route of Administration (Grid Representation)

6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Aprea Therapeutics
6.2.1. Company Overview
6.2.2. DNA Damage Response Targeting Therapeutics Portfolio
6.2.3. Recent Developments and Future Outlook
6.3. AstraZeneca
6.3.1 Company Overview
6.3.2. DNA Damage Response Targeting Therapeutics Portfolio
6.3.3. Recent Developments and Future Outlook
6.4. Chordia Therapeutics
6.4.1 Company Overview
6.4.2. DNA Damage Response Targeting Therapeutics Portfolio
6.4.3. Recent Developments and Future Outlook
6.5. Mission Therapeutics
6.5.1 Company Overview
6.5.2. DNA Damage Response Targeting Therapeutics Portfolio
6.5.3. Recent Developments and Future Outlook
6.6. Repare Therapeutics
6.6.1 Company Overview
6.6.2. DNA Damage Response Targeting Therapeutics Portfolio
6.6.3. Recent Developments and Future Outlook
6.7. Senhwa Biosciences
6.7.1 Company Overview
6.7.2. DNA Damage Response Targeting Therapeutics Portfolio
6.7.3. Recent Developments and Future Outlook

7. CLINICAL TRIALS ANALYSIS
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. DNA Damage Response Targeting Therapeutics: Clinical Trial Analysis
7.3.1. Analysis by Trial Registration Year
7.3.2. Analysis by Number of Patients Enrolled
7.3.3. Analysis by Gender of Patients Enrolled
7.3.4. Analysis by Trial Phase
7.3.5. Analysis by Recruitment Status
7.3.6. Analysis by Study Design
7.3.7. Analysis by Type of Sponsor / Collaborator
7.3.8. Analysis by Therapeutic Area
7.3.9. Reginal Analysis
7.3.10. Case Study
7.3.11. Most Active Industry Players: Analysis by Number of Clinical Trails
7.3.12. Concluding Remarks

8. PUBLICATION ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. DNA Damage Response Targeting Therapeutics: List of Recent Publications
8.3.1. Analysis by Year of Publication
8.3.2. Analysis by Type of Publication
8.3.3. Emerging Focus Areas
8.3.4. Analysis by Key Research Journals
8.3.4.1. Most Prominent Journals: Analysis by Number of Publications
8.3.4.2. Analysis by Journal Impact Factor
8.3.4.3. Most Prominent Journals: Analysis by Journal Impact Factor
8.3.5. Analysis by Key Research Hubs
8.3.6. Analysis by Target Molecule
8.3.6.1. Most Popular Target Molecule: Analysis by Number of Publications
8.3.6.2. Analysis by Year and Target Molecule
8.3.7. Analysis by Grants Awarded
8.3.7.1. Locations of Grant Awarding Organizations: Analysis by Number of Publications
8.3.8. Publication Benchmarking Analysis

9. ANALYSIS OF KEY PARAMETERS IMPACTING DRUG PRICING AND ADOPTION
9.1. Chapter Overview
9.2. Key Market Drivers
9.3. Publisher Framework
9.3.1. Benchmarking Parameters
9.3.2. Methodology
9.3.3. Impact on Price and Adoption
9.3.4. Impact on Pricing and Adoption of Individual Drugs / Drug Candidates
9.3.4.1. Adavosertib
9.3.4.2. APX3330
9.3.4.3. ASLAN003
9.3.4.4. CBP-501
9.3.4.5. Eprenetapopt
9.3.4.6. Irofulven
9.3.4.7. LB-100
9.3.4.8. Silmitasertib
9.3.4.9. TRC-102
9.3.5. Concluding Remarks

10. MARKET FORECAST
10.1. Chapter Overview
10.2. Scope and Limitations
10.3. Forecast Methodology and Key Assumptions
10.4. Global DNA Damage Response Targeting Therapeutics Market, 2021-2030
10.4.1. DNA Damage Response Targeting Therapeutics Market: Distribution by Target Disease Indication, 2021 and 2030
10.4.1.1. DNA Damage Response Targeting Therapeutics Market for Acute Myeloid Leukemias, 2021-2030
10.4.1.2. DNA Damage Response Targeting Therapeutics Market for COVID-19, 2021-2030
10.4.1.3. DNA Damage Response Targeting Therapeutics Market for Diabetic Macular Edemas, 2021-2030
10.4.1.4. DNA Damage Response Targeting Therapeutics Market for Mesotheliomas, 2021-2030
10.4.1.5. DNA Damage Response Targeting Therapeutics Market for Myelodysplastic Syndromes, 2021-2030
10.4.1.6. DNA Damage Response Targeting Therapeutics Market for Non-Squamous Non-Small Cell Lung Cancers, 2021-2030
10.4.1.7. DNA Damage Response Targeting Therapeutics Market for Prostate Cancers, 2021-2030
10.4.1.8. DNA Damage Response Targeting Therapeutics Market for Uterine Serous Carcinomas, 2021-2030
10.4.2. DNA Damage Response Targeting Therapeutics Market: Distribution by Therapeutic Area, 2021 and 2030
10.4.2.1. DNA Damage Response Targeting Therapeutics Market for Hematological Malignancies, 2021-2030
10.4.2.2. DNA Damage Response Targeting Therapeutics Market for Solid Tumors, 2021-2030
10.4.2.3. DNA Damage Response Targeting Therapeutics Market for Other Disorders, 2021-2030
10.4.3. DNA Damage Response Targeting Therapeutics Market: Distribution by Target Molecule, 2021 and 2030
10.4.3.1. DNA Damage Response Targeting Therapeutics Market for APE1/Ref-1, 2021-2030
10.4.3.2. DNA Damage Response Targeting Therapeutics Market for Casein Kinase 2, 2021-2030
10.4.3.3. DNA Damage Response Targeting Therapeutics Market for CHK-1, 2021-2030
10.4.3.4. DNA Damage Response Targeting Therapeutics Market for C-Tak, 2021-2030
10.4.3.5. DNA Damage Response Targeting Therapeutics Market for DHODH, 2021-2030
10.4.3.6. DNA Damage Response Targeting Therapeutics Market for MAPKAPK2, 2021-2030
10.4.3.7. DNA Damage Response Targeting Therapeutics Market for p53, 2021-2030
10.4.3.8. DNA Damage Response Targeting Therapeutics Market for Protein Phosphatase 2A, 2021-2030
10.4.3.9. DNA Damage Response Targeting Therapeutics Market for WEE1, 2021-2030
10.4.4. DNA Damage Response Targeting Therapeutics Market: Distribution by Type of Molecule, 2021 and 2030
10.4.4.1. DNA Damage Response Targeting Therapeutics Market for Biologics, 2021-2030
10.4.4.2. DNA Damage Response Targeting Therapeutics Market for Small Molecules, 2021-2030 
10.4.5. DNA Damage Response Targeting Therapeutics Market: Distribution by Route of Administration, 2021 and 2030
10.4.5.1. DNA Damage Response Targeting Therapeutics Market for Oral Drugs, 2021-2030
10.4.5.2. DNA Damage Response Targeting Therapeutics Market for Intravenous Drugs, 2021-2030
10.4.6. DNA Damage Response Targeting Therapeutics Market: Distribution by Geography, 2021 and 2030
10.4.6.1. DNA Damage Response Targeting Therapeutics Market in the US, 2021-2030
10.4.6.2. DNA Damage Response Targeting Therapeutics Market in Canada, 2021-2030
10.4.6.2. DNA Damage Response Targeting Therapeutics Market in Denmark, 2021-2030
10.4.6.2. DNA Damage Response Targeting Therapeutics Market in France, 2021-2030
10.4.6.3. DNA Damage Response Targeting Therapeutics Market in Germany, 2021-2030
10.4.6.4. DNA Damage Response Targeting Therapeutics Market in Italy, 2021-2030
10.4.6.5. DNA Damage Response Targeting Therapeutics Market in Spain, 2021-2030
10.4.6.6. DNA Damage Response Targeting Therapeutics Market in the UK, 2021-2030
10.4.6.7. DNA Damage Response Targeting Therapeutics Market in Australia, 2021-2030
10.4.6.8. DNA Damage Response Targeting Therapeutics Market in Singapore, 2021-2030
10.4.6.9. DNA Damage Response Targeting Therapeutics Market in South Korea, 2021-2030
10.4.7. Drug-wise Sales Forecast
10.4.6.1 Adavosertib (AZD1775, MK-1775), AstraZeneca
10.4.6.1.1. Target Patient Population
10.4.6.1.2. Sales Forecast
10.4.6.1.3. Net Present Value
10.4.6.1.4. Value Creation Analysis
10.4.6.2. APX3330, Apexian Pharmaceuticals
10.4.6.2.1. Target Patient Population
10.4.6.2.2. Sales Forecast
10.4.6.2.3. Net Present Value
10.4.6.2.4. Value Creation Analysis
10.4.6.3. ASLAN003 (LAS 186323), Aslan Pharmaceuticals
10.4.6.3.1. Target Patient Population
10.4.6.3.2. Sales Forecast
10.4.6.3.3. Net Present Value
10.4.6.3.4. Value Creation Analysis
10.4.6.4. CBP-501, CanBas
10.4.6.4.1. Target Patient Population
10.4.6.4.2. Sales Forecast
10.4.6.4.3. Net Present Value
10.4.6.4.4. Value Creation Analysis
10.4.6.5. Eprenetapopt, Aprea Therapeutics
10.4.6.5.1. Target Patient Population
10.4.6.5.2. Sales Forecast
10.4.6.5.3. Net Present Value
10.4.6.5.4. Value Creation Analysis
10.4.6.6. Irofulven, Allarity Therapeutics
10.4.6.6.1. Target Patient Population
10.4.6.6.2. Sales Forecast
10.4.6.6.3. Net Present Value
10.4.6.6.4. Value Creation Analysis
10.4.6.7. LB-100 (Lixte Biotechnology)
10.4.6.7.1. Target Patient Population
10.4.6.7.2. Sales Forecast
10.4.6.7.3. Net Present Value
10.4.6.7.4. Value Creation Analysis
10.4.6.8. Silmitasertib, Senhwa Biosciences
10.4.6.8.1. Target Patient Population
10.4.6.8.2. Sales Forecast
10.4.6.8.3. Net Present Value
10.4.6.8.4. Value Creation Analysis
10.4.9 Concluding Remarks

11. CONCLUDING REMARKS

12. APPENDIX I: TABULATED DATA

13. APPENDIX II: LIST OF COMPANIES AND ORGANIZATION

Note: Product cover images may vary from those shown
  • AbbVie
  • Agios Pharmaceuticals
  • Allarity Therapeutics
  • Ankrin Therapeutics
  • Apexian Pharmaceuticals
  • ApoGen Biotechnologies
  • Aprea Therapeutics
  • Aptose Biosciences
  • Artios Pharma
  • Aslan Pharmaceuticals
  • AstraZeneca
  • Atrin Pharmaceuticals
  • Bayer
  • BDC Capital
  • BenevolentAI
  • Breakpoint Therapeutics
  • Bristol Myers Squibb
  • BVF Partners
  • CanBas
  • Cancer Research UK
  • Canadian Institutes of Health Research (CIHR)
  • China Scholarship Council
  • Chordia Therapeutics
  • CLINUVEL PHARMACEUTICALS
  • Cowen Healthcare Investments
  • Cybrexa Therapeutics
  • Cyclacel Pharmaceuticals
  • Cyteir Therapeutics
  • Daiichi Sankyo
  • Debiopharm
  • Deutsche Forschungsgemeinschaft
  • EMD Serono
  • EryDel
  • Fonds de solidarité FTQ
  • FoRx Therapeutics
  • Grant Agency of the Slovak Republic
  • Health Effects Institute
  • HealthCap
  • The United States Department of Health and Human Services (HHS)
  • IDEAYA Biosciences
  • Impact Therapeutics
  • Ministry of Science and Innovation of Spain 
  • Innovative Genomics Institute (IGI)
  • JAFCO
  • Karolinska Development
  • Kazan Federal University
  • Kinnate Biopharma
  • Kyoto University Innovation Capital
  • Lixte Biotechnology
  • Logos Capital
  • Merck
  • Merck KGaA
  • Ministry of Science and ICT 
  • Mission Therapeutics
  • Massachusetts Institute of Technology (MIT)
  • Mitsubishi UFJ Capital
  • MPM Capital
  • National Institutes of Health (NIH)
  • National Institute of Allergy and Infectious Diseases (NIAID)
  • National Institute of General Medical Sciences
  • National Natural Science Foundation of China (NSFC)
  • National Research Foundation of Korea (NRF)
  • National Science Center
  • Natural Science Foundation of Inner Mongolia
  • NeoPhore
  • ONO Pharmaceutical
  • Onxeo
  • OrbiMed
  • Orchard Therapeutics
  • Patrys
  • Pfizer
  • PharmaEngine
  • PhoreMost
  • Rain Therapeutics
  • Redmile
  • Repare Therapeutics
  • Rock Springs Capital
  • 5AM Ventures 
  • Rocket Pharmaceuticals 
  • Sao Paulo Research Foundation (FAPESP)
  • University of Texas MD Anderson Cancer Center
  • Sectoral Asset Management
  • Senhwa Biosciences
  • Shinsei Capital Partners
  • Sierra Oncology
  • SMBC Venture Capital
  • SyntheX
  • Tarveda Therapeutics
  • Tempest Therapeutics
  • TRACON Pharmaceuticals
  • Triplet Therapeutics
  • Vernalis
  • Versant Ventures
  • Vertex Pharmaceuticals
  • Swedish Research Council 
  • Zentalis Pharmaceuticals
Note: Product cover images may vary from those shown

 

 

Loading
LOADING...

Adroll
adroll